Atlas Trials

First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Clinical trial NCT02335814 · TERMINATED

Trial details

NCT number
NCT02335814
Sponsor
RAPT Therapeutics, Inc.
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Acute Myeloid Leukemia
Start date
2015-04-08
Primary completion
2017-05-03
Enrollment
51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.